The only non-hormonal drug for menopause symptoms arrives in Spain

Fezolinetant (Veosa), the only non-hormonal pharmacological treatment for moderate to severe vasomotor symptoms associated with menopause (VMS), is now available in Spain. such as hot flashes and night sweats, which affect up to 80% of women. at this stage of his life.

SVM They originate in the hypothalamus, the part of the brain responsible for regulating body temperature. through neurons called KNDy. Under normal conditions, there is a balance between estrogen, which inhibits these neurons, and the brain substance neurokinin B (NKB), which stimulates them. During menopause, when estrogen levels decline, this balance is lost, causing the hypothalamus to interpret that the body is warm when in fact it is not, and trigger SMS.

Fezolinetant is an oral, selective neurokinin 3 (NK3) receptor antagonist that acts by blocking the binding of neurokinin B to KNDy neurons. Thus, it helps restore thermoregulatory balance, reducing the frequency and intensity of hot flashes and night sweats. “This new drug adds to the therapeutic arsenal against hot flashes during menopause, a symptom that many women tend to put up with. Provides an alternative for those who do not want or cannot use hormonal treatment.“, notes Dr. Maria Facero, Doctor of Gynecology and Obstetrics at the University Hospital of La Zarzuela and representative of the Spanish Association for the Study of Menopause (AEEM).

“Moderate to severe hot flashes can have a major impact on the quality of life of menopausal women. Those that are accompanied by sweating are considered moderate, and those that reach the point of forcing you to stop activities are considered severe. normal. Both can affect mood, personal relationships, work life, concentration, social activities and even self-care,” says Santiago Palacios, a gynecologist and director of the Palacios Institute of Women’s Health and Medicine.

Efficiency

Its effectiveness, safety and tolerability are based on the results of the Bright Sky clinical program, which included three clinical studies involving more than 3,000 women with moderate to severe IUDs. In parallel, results from the phase 3b Dayligth clinical trial showed a statistically significant reduction in the incidence of moderate to severe SMS from baseline to week 4 for fezolinetant 45 mg once daily compared with placebo. In addition, the effects of fezolinantane are observed from the first week of administration.